| Outcome . | n (%) . |
|---|---|
| Tumor stage after complete neoadjuvant therapy by ERUS | |
| 0 | 1 (7) |
| I | 2 (13) |
| II | 7 (47) |
| III | 5 (33) |
| Surgery procedure performed | |
| APR | 2 (12) |
| LAR | 15 (88) |
| NAR score, as defined from NSABP R‐04 | |
| Low (<8) | 1 (6) |
| Intermediate (8–16) | 12 (71) |
| High (>16) | 4 (24) |
| Median (range) | 14.98 (0.94–41.62) |
| NAR quantiles | |
| 1st (<8.5) | 7 (41) |
| 2nd and 3rd (8.5–15.0) | 6 (35) |
| 4th (>15.0) | 4 (24) |
| Overall survival, median (95% CI), mo | Not reached |
| Disease‐free survival, median (95% CI), mo | Not reached |
| Duration follow‐up, median (range), mo | 44.8 (27.4–63.9) |
| Outcome . | n (%) . |
|---|---|
| Tumor stage after complete neoadjuvant therapy by ERUS | |
| 0 | 1 (7) |
| I | 2 (13) |
| II | 7 (47) |
| III | 5 (33) |
| Surgery procedure performed | |
| APR | 2 (12) |
| LAR | 15 (88) |
| NAR score, as defined from NSABP R‐04 | |
| Low (<8) | 1 (6) |
| Intermediate (8–16) | 12 (71) |
| High (>16) | 4 (24) |
| Median (range) | 14.98 (0.94–41.62) |
| NAR quantiles | |
| 1st (<8.5) | 7 (41) |
| 2nd and 3rd (8.5–15.0) | 6 (35) |
| 4th (>15.0) | 4 (24) |
| Overall survival, median (95% CI), mo | Not reached |
| Disease‐free survival, median (95% CI), mo | Not reached |
| Duration follow‐up, median (range), mo | 44.8 (27.4–63.9) |
Abbreviations: APR, abdominal perineal resection; CI, confidence interval; ERUS, endorectal ultrasound; LAR, low anterior resection; NAR, neoadjuvant rectal.
| Outcome . | n (%) . |
|---|---|
| Tumor stage after complete neoadjuvant therapy by ERUS | |
| 0 | 1 (7) |
| I | 2 (13) |
| II | 7 (47) |
| III | 5 (33) |
| Surgery procedure performed | |
| APR | 2 (12) |
| LAR | 15 (88) |
| NAR score, as defined from NSABP R‐04 | |
| Low (<8) | 1 (6) |
| Intermediate (8–16) | 12 (71) |
| High (>16) | 4 (24) |
| Median (range) | 14.98 (0.94–41.62) |
| NAR quantiles | |
| 1st (<8.5) | 7 (41) |
| 2nd and 3rd (8.5–15.0) | 6 (35) |
| 4th (>15.0) | 4 (24) |
| Overall survival, median (95% CI), mo | Not reached |
| Disease‐free survival, median (95% CI), mo | Not reached |
| Duration follow‐up, median (range), mo | 44.8 (27.4–63.9) |
| Outcome . | n (%) . |
|---|---|
| Tumor stage after complete neoadjuvant therapy by ERUS | |
| 0 | 1 (7) |
| I | 2 (13) |
| II | 7 (47) |
| III | 5 (33) |
| Surgery procedure performed | |
| APR | 2 (12) |
| LAR | 15 (88) |
| NAR score, as defined from NSABP R‐04 | |
| Low (<8) | 1 (6) |
| Intermediate (8–16) | 12 (71) |
| High (>16) | 4 (24) |
| Median (range) | 14.98 (0.94–41.62) |
| NAR quantiles | |
| 1st (<8.5) | 7 (41) |
| 2nd and 3rd (8.5–15.0) | 6 (35) |
| 4th (>15.0) | 4 (24) |
| Overall survival, median (95% CI), mo | Not reached |
| Disease‐free survival, median (95% CI), mo | Not reached |
| Duration follow‐up, median (range), mo | 44.8 (27.4–63.9) |
Abbreviations: APR, abdominal perineal resection; CI, confidence interval; ERUS, endorectal ultrasound; LAR, low anterior resection; NAR, neoadjuvant rectal.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
